In a study of 81 patients with NSCLC, Bing et al. showed that an increase in CD34-MVD was associated with tumor progression but not lymph node metastasis; unfortunately, the study did not include a survival analysis [15]. This evidence concerns the gene CD34 and metastatic malignant neoplasm in the lymph nodes.